Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Trend | Peers | Company |
---|---|---|
Is return on equity increasing? | No | Yes |
Is net profit margin increasing? | Yes | Yes |
Is asset turnover increasing? | No | No |
Is equity multiplier increasing? | No | Yes |
Competitors Used |
---|
Glenmark Pharmaceuticals Limited |
Lupin Limited |
Mankind Pharma Limited |
Alembic Pharmaceuticals Limited |
Medico Remedies Limited |
Return on Equity Benchmarks | ||||||||
Comparable Companies | ||||||||
532,296 | 500,257 | 543,904 | 533,573 | 540,937 | ABBOTINDIA | |||
Return On Equity | ||||||||
Latest Twelve Months | NA | NA | NA | NA | NA | NA | ||
Fiscal Year - 1 | -2% | 3% | 19% | 7% | 18% | 32% | ||
Fiscal Year - 2 | 12% | -12% | 26% | 10% | 14% | 29% | ||
Fiscal Year - 3 | 15% | 9% | 31% | 28% | 8% | 27% | ||
Fiscal Year - 4 | 13% | -3% | 33% | 28% | 6% | 27% | ||
Fiscal Year - 5 | 17% | 4% | 20% | 24% | 6% | 24% | ||
Average | 11% | 0% | 26% | 19% | 10% | 28% | ||
Median | 13% | 3% | 26% | 24% | 8% | 27% | ||
Benchmarks | Ticker | |||||||
Glenmark Pharmaceuticals Limited | BSE:532296 | |||||||
Lupin Limited | BSE:500257 | |||||||
Mankind Pharma Limited | BSE:543904 | |||||||
Alembic Pharmaceuticals Limited | BSE:533573 | |||||||
Medico Remedies Limited | BSE:540937 |
Financial Performance | ||||||||
Comparable Companies | ||||||||
(in millions) | May-57 | Aug-69 | Feb-89 | Nov-60 | Jan-81 | ABBOTINDIA | ||
Latest Fiscal Year | Mar-24 | Mar-24 | Mar-24 | Mar-24 | Mar-24 | Mar-24 | ||
LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
Revenues | ||||||||
Latest Twelve Months | 139,608 | 220,016 | 116,410 | 64,194 | 1,510 | 62,432 | ||
Fiscal Year | 126,454 | 200,108 | 103,348 | 62,286 | 1,449 | 58,489 | ||
Fiscal Year - 1 | 116,556 | 166,417 | 87,494 | 56,526 | 1,404 | 53,487 | ||
Fiscal Year - 2 | 123,049 | 164,055 | 77,816 | 53,058 | 1,210 | 49,133 | ||
Fiscal Year - 3 | 109,439 | 151,630 | 62,144 | 53,931 | 1,224 | 43,100 | ||
Fiscal Year - 4 | 106,573 | 153,748 | 58,719 | 46,058 | 886 | 40,931 | ||
Fiscal Year - 5 | 98,655 | 146,646 | 49,800 | 39,347 | 977 | 36,786 | ||
Net Income | ||||||||
Latest Twelve Months | (2,002) | 28,685 | 20,414 | 6,047 | 89 | 13,345 | ||
Fiscal Year | (18,990) | 19,145 | 19,129 | 6,158 | 83 | 12,012 | ||
Fiscal Year - 1 | (1,697) | 4,301 | 12,819 | 3,420 | 72 | 9,494 | ||
Fiscal Year - 2 | 9,417 | (15,280) | 14,335 | 5,209 | 48 | 7,987 | ||
Fiscal Year - 3 | 9,700 | 12,165 | 12,654 | 11,465 | 26 | 6,907 | ||
Fiscal Year - 4 | 7,760 | (3,995) | 10,304 | 8,288 | 16 | 5,929 | ||
Fiscal Year - 5 | 9,250 | 5,121 | 5,785 | 5,844 | 16 | 4,503 | ||
Total Assets | ||||||||
Latest Fiscal Quarter Prior | NA | NA | NA | NA | NA | NA | ||
Latest Fiscal Quarter | NA | NA | NA | NA | NA | NA | ||
Fiscal Year | 143,586 | 239,972 | 119,633 | 64,456 | 962 | 51,935 | ||
Fiscal Year - 1 | 193,717 | 229,559 | 97,154 | 61,828 | 874 | 45,555 | ||
Fiscal Year - 2 | 170,833 | 218,212 | 91,477 | 71,220 | 774 | 42,241 | ||
Fiscal Year - 3 | 156,036 | 236,104 | 63,726 | 67,090 | 756 | 38,405 | ||
Fiscal Year - 4 | 146,848 | 249,839 | 50,733 | 59,891 | 753 | 35,469 | ||
Fiscal Year - 5 | 132,956 | 279,494 | 41,124 | 47,778 | 763 | 29,409 | ||
Fiscal Year - 6 | 125,954 | 263,054 | NA | 39,411 | 594 | 24,162 | ||
Common Equity | ||||||||
Latest Fiscal Quarter Prior | 93,271 | 132,387 | 84,284 | 44,700 | 476 | 31,089 | ||
Latest Fiscal Quarter | 84,457 | 156,418 | 105,648 | 48,881 | 555 | 35,211 | ||
Fiscal Year | 78,479 | 142,903 | 93,631 | 48,182 | 524 | 36,989 | ||
Fiscal Year - 1 | 94,739 | 124,645 | 74,352 | 43,705 | 438 | 31,885 | ||
Fiscal Year - 2 | 90,866 | 121,533 | 61,552 | 52,376 | 366 | 28,198 | ||
Fiscal Year - 3 | 70,646 | 138,031 | 47,220 | 50,670 | 325 | 26,022 | ||
Fiscal Year - 4 | 60,705 | 125,367 | 34,853 | 32,194 | 299 | 24,317 | ||
Fiscal Year - 5 | 56,052 | 137,422 | 28,231 | 27,188 | 282 | 20,086 | ||
Fiscal Year - 6 | 51,635 | 135,771 | NA | 22,201 | 267 | 16,928 |